CC
ASND icon

Centiva Capital’s Ascendis Pharma A/S ASND Stock Holding History

Centiva Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,500
Closed -$305K – 1511
2022
Q4 		$305K Buy
+2,500
New +$290K 0.01% 950
2022
Q1 		– Sell
-3,200
Closed -$430K – 1607
2021
Q4 		$430K Buy
+3,200
New +$476K 0.01% 837

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Centiva Capital's ASND Position: Q2 2023 in Review

Centiva Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2023, closing a stake of 220 shares — an estimated $19.1K sold.

Centiva Capital first reported a position in ASND in Q4 2021 and held it in 3 quarters. The position peaked at $221K in Q4 2021. 157 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

  • Centiva Capital reported no remaining Ascendis Pharma A/S position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 220 Ascendis Pharma A/S shares in Q2 2023, an estimated $19.1K.
  • Centiva Capital first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 3 quarters.
  • Centiva Capital's Ascendis Pharma A/S position peaked at $221K in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.